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Compromised LCAT Function Is Associated With
Increased Atherosclerosis
G. Kees Hovingh, MD; Barbara A. Hutten, PhD; Adriaan G. Holleboom, MD; Wilma Petersen, BSc;
Patrick Rol, BSc; Anton Stalenhoef, MD, PhD; Aeilko H. Zwinderman, PhD; Eric de Groot, MD, PhD;
John J.P. Kastelein MD, PhD; Jan Albert Kuivenhoven, PhD
Background—Prospective epidemiological studies have shown that low plasma levels of HDL cholesterol (HDL-C) are
associated with an increased risk for cardiovascular disease (CVD). Despite nearly 40 years of research, however, it is
unclear whether this also holds true for individuals with severely reduced levels of HDL-C due to mutations in the
lecithin:cholesterol acyltransferase (LCAT) gene. Better insight into CVD risk in these individuals may provide clues
toward the potential of LCAT as a pharmaceutical target to raise HDL-C levels.
Methods and Results—Lipids, lipoproteins, high-sensitivity C-reactive protein (CRP), and carotid artery intima-media
thickness (IMT) were assessed in 47 heterozygotes for LCAT gene mutations and 58 family controls. Compared with
controls, heterozygotes presented with a mean 36% decrease in HDL-C levels (P0.0001), a 23% increase in
triglyceride levels (P0.0001), and a 2.1-fold increase in CRP levels (P0.0001). Mean carotid IMT was significantly
increased in heterozygotes compared with family controls (0.6230.13 versus 0.5910.08 mm). After adjustment for
age, gender, and alcohol use, this difference proved statistically significant (P0.0015).
Conclusions—The data show that heterozygosity for LCAT gene defects is associated with low HDL-C levels and elevated
concentration of triglycerides and CRP in plasma. This phenotype underlies increased IMT in carriers versus controls,
which suggests that LCAT protects against atherosclerosis. This in turn indicates that targeting LCAT to raise HDL-C
may reduce CVD risk. (Circulation. 2005;112:879-884.)
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Despite the widespread use of pharmacological agentsthat can effectively decrease LDL cholesterol (LDL-C),
the vast majority of patients at increased risk for atheroscle-
rosis continue to have cardiovascular disease (CVD). This
underscores the need for additional therapeutic strategies. In
this respect, drugs that increase HDL cholesterol (HDL-C)
hold promise. In addition to its pivotal role in reverse
cholesterol transport, HDL also exerts antithrombotic, anti-
oxidant, and antiinflammatory properties,1,2 which illustrates
that increasing HDL-C levels may result in various beneficial
effects.
Hereditary disorders of human HDL metabolism, such as
deficiencies of apolipoprotein (apo) A-I, ATP binding cas-
sette A1 (ABCA1), lecithin:cholesterol acyltransferase
(LCAT), and cholesteryl ester transfer protein (CETP) have
been crucial to our understanding of the reverse cholesterol
transport pathway. Consequently, they have proven important
in the identification of therapeutic targets to increase HDL-C.
This is exemplified by the recent materialization of inhibitors
of CETP that exhibit strong HDL-C–raising potential in
clinical trials.3,4 Also, increasing the function of ABCA1, a
transmembrane protein that promotes the efflux of cholesterol
and phospholipids, is thought to reduce CVD risk. This
assumption is among others that are based on the finding that
mutations in the ABCA1 gene are associated with increased
risk for atherosclerosis in humans.5 This has led to the search
for molecules that selectively enhance ABCA1 function.6
HDL deficiency and increased risk of coronary artery disease
have also been described in families with apoA-I muta-
tions.7,8 Supported by convincing epidemiological evidence
of the protective role of apoA-I, this has further established
this protein as a promising target to reduce coronary artery
disease risk. This knowledge has recently prompted the use of
infusion of apoA-I–containing phospholipid complexes in
patients with acute coronary syndrome, which was shown to
induce regression of coronary atheroma.9
LCAT deficiency represents another rare, recessive genetic
disorder that underlies HDL deficiency. LCAT is a plasma
enzyme that esterifies free cholesterol, primarily at the
surface of the HDL particle, after which the cholesteryl ester
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molecules migrate to the inner core of this lipoprotein.
Through this action, LCAT plays a key role in the maturation
of HDL particles.10 Norum and Gjone11 first described that
LCAT gene mutations underlie familial LCAT deficiency.
Later, it was recognized that a less severe clinical phenotype,
fish-eye disease, results from mutations in this very gene.12
Familial LCAT deficiency and fish-eye disease are both
characterized by HDL deficiency (5% to 10% of normal
HDL-C levels). (For a review of the effect of LCAT mutations
on lipid metabolism, see Pritchard and Hill.13)
Although LCAT has thus long been known to play an
important role in HDL metabolism, its association with
atherosclerosis has remained elusive. This is mainly because
of the very limited numbers of carriers of LCAT gene
mutations. In addition, animal data have provided conflicting
results.14,15 We therefore set out to study the relationships
between LCAT and atherosclerosis using B-mode ultrasound
intima-media thickness (IMT) measurements of the carotid
arteries as a validated marker for CVD risk and atheroscle-
rosis in large cohort of LCAT mutation carriers.
Methods
Study Groups
Over the past 14 years, our laboratory has, in collaboration with the
laboratory of Dr P.H. Pritchard, characterized 5 families of Dutch
Caucasian descent with LCAT deficiency disorders. Families 1,16
2,17,18 and 319 have been described previously. The probands of these
3 families experienced corneal clouding and consulted ophthalmol-
ogists before being referred to our Lipid Clinic. More recently, we
identified 2 additional probands with LCAT deficiency disorders
(families 4 and 5, respectively), but these data were not published.
Briefly, the proband of family 4 male, aged 68 years, was referred to
our Lipid Clinic for low HDL-C levels. Upon physical examination,
corneal opacities were noted, whereas laboratory tests showed an
HDL-C level of 0.15 mmol/L. LCAT activity was assessed by using
a proteoliposome substrate20 and was severely reduced, which was
related to compound heterozygosity for 2 missense mutations (un-
derlying P10Q and V309M, respectively). The proband of family 5,
a 20-year-old woman, was referred to our Lipid Clinic for corneal
clouding. She had HDL deficiency (HDL-C 0.09 mmol/L), and her
plasma LCAT activity was severely reduced due to compound
heterozygosity for point mutations that caused amino acid substitu-
tions at positions 123 (T123I) and 309 (V309M) of the mature LCAT
protein.
For the present cross-sectional analysis, the probands and their
family members of the aforementioned 5 families were invited to
participate in an IMT study irrespective of cardiovascular or genetic
status; no inclusion or exclusion criteria were used. The recruitment
of study individuals was performed as follows: we contacted the
index patients of the families who were previously found to be
homozygous or compound heterozygous for LCAT gene mutations.
Using these individuals as central spokespersons, family members
were invited to participate by our physicians and genetic field
workers (sometimes through the organization of family reunions).
This was done through a letter and/or by telephone. Family members
included both first- and second-degree relatives and those who had
married into the family.
All LCAT gene defects under study have previously been shown to
underlie marked loss of LCAT activity (30% to 42% compared with
family controls), which has as its direct consequence a 30% to 38%
reduction of HDL-C levels.16,19,21 We therefore only genotyped the
participants (using previously described methods16,18,19,21) to distin-
guish between carriers and noncarriers. Heterozygotes for LCAT
gene mutations do not have clinical signs or complaints despite
having these marked reductions of HDL-C levels. Thus, importantly,
there existed no clinical recruitment bias for the heterozygotes. From
families 1, 2, 3, 4, and 5, we recruited 3, 2, 30, 6, and 6 heterozygotes
and 6, 0, 45, 3, and 4 controls, respectively.
Nine homozygotes or compound heterozygotes, characterized by
near complete HDL-C deficiency, also underwent IMT measure-
ments (average IMT was 0.7302 mm). However, the low number
and the completely different age distribution (60.915.6 versus
41.916.1 and 42.217.4 years in controls and heterozygotes,
respectively) unfortunately could not provide the required statistical
foundation for solid conclusions with regard to the impact of LCAT
on atherosclerosis. The data from this group were therefore not used
for further analysis.
Past medical history, presence of cardiovascular risk factors, and
use of medication were assessed by questionnaire. The data on
clinical events were verified by studying the clinical records.
Informed consent was obtained for plasma sampling, storage, genetic
analysis, and IMT measurements. The study was approved by the
Ethics Committee of the Academic Medical Center in Amsterdam.
Blood Analyses
Blood was collected in EDTA-coated tubes after overnight fasting.
Total cholesterol, triglycerides, and HDL-C were measured by
established methods, and LDL-C was calculated by the equation of
Friedewald.22 Plasma apoA-I and apoB were measured with the
Nephelometric BNll System (Dade Behring).23,24 High-sensitivity
C-reactive protein (hs-CRP) levels were measured by the Dade
Behring method. LCAT activity measurements were performed with
an exogenous apoA-I proteoliposome substrate as described
previously.20
Carotid Artery IMT and CVD
IMT measurements were performed in a standardized fashion for
both the carriers of LCAT gene mutations and the controls, as
described previously.25 Briefly, an Acuson 128XP/10v (Acuson
Corporation) equipped with a 7.0-MHz linear-array transducer was
used to obtain B-mode ultrasound images. The following wall
segments were bilaterally scanned over a length of 10 mm: the
common carotid artery, the carotid bulb, and the internal carotid
artery. Images were saved as JPEG image files, and a reader, blinded
for the genetic status of the patient, measured the IMT of the far wall
of the respective segments. The mean combined outcome of the 6
segments was used for analysis.
A vascular event was defined by the presence of at least 1 of the
following: acute myocardial infarction, percutaneous coronary inter-
vention, coronary artery bypass grafting, and angina pectoris, as well
as by the presence of peripheral or cerebrovascular disease. Cardio-
vascular events were ascertained by use of questionnaires and
verified by studying the clinical records.
Statistical Analysis
Results are expressed as means (SD), except for triglycerides,
lipoprotein(a), and hs-CRP levels, which are expressed as medians
(interquartile range) because of a skewed distribution. These vari-
ables were log-transformed before statistical analysis. Differences in
terms of demographic and lifestyle characteristics between heterozy-
gotes for LCAT gene mutations and family controls were evaluated
with linear or logistic regression analyses with generalized estimat-
ing equations in the SAS procedure GENMOD to account for
correlations within families. For differences in blood pressure,
smoking, and alcohol use, we made adjustments in a multivariate
model for age and gender.
To evaluate differences between the 2 groups in biochemical
characteristics and mean carotid IMT, we used the same SAS
procedure, allowing for clustering within families (due to clustering
of genetic and/or environmental factors). For the biochemical char-
acteristics, we adjusted for age, gender and smoking using multivar-
iate models. For mean carotid IMT, the main outcome of this study,
a more elaborate procedure was used. We first explored univariately
the relation between mean carotid IMT and baseline variables.
Hereafter, using multivariate models, we identified independent
predictors after stepwise backward selection. For all generalized
880 Circulation August 9, 2005
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estimating equation models, the exchangeable correlation structure
was used. The difference between controls and LCAT heterozygotes
was tested by assessing their interaction (age and group). Probability
values0.05 were considered significant. For statistical analyses the
SAS package (release 8.02; SAS Institute Inc) was used.
Results
Genetic and Demographic Characteristics of the
Study Groups
A total of 47 heterozygotes for LCAT gene mutations and 58
controls (ascertained by genotyping) were recruited from 5
families of Dutch descent originating from different parts of
The Netherlands. Mean average age was nearly identical
among the heterozygotes and controls (42.2 versus 41.9 years
of age, respectively; Table 1). Males were slightly more
prevalent among the heterozygotes (62%) than among con-
trols (47%), but this did not reach statistical significance
(P0.062). Systolic and diastolic blood pressure and alcohol
use did not differ among the groups. The percentage of
smokers, however, was significantly higher in the heterozy-
gotes than in the controls (21% versus 14%; P0.015). One
heterozygous carrier and 2 subjects in the control group had
been prescribed a statin. No patient had diabetes mellitus,
defined as use of oral antidiabetic drugs or insulin.
The data on LCAT activity levels represent data from
previous publications.16,18,19,21 In these reports, the LCAT
mutations in the respective families have been shown to
result in 30% to 42% reductions in LCAT activity,
with concomitant 30% to 38% reductions in HDL-C levels
in the heterozygous carriers compared with family
controls.
Lipids, (Apo)lipoproteins, and C-Reactive
Protein Levels
Table 2 gives the raw data accompanied by probability values
adjusted for age, gender, smoking, and family. Compared
with family controls, heterozygotes exhibited a mean 36%
decrease in HDL-C levels and a mean 22% decrease in
apoA-I levels (P0.0001 for both). Mean triglyceride levels
were, in contrast, increased by 23% (P0.026). In the
presence of unchanged total cholesterol levels, the heterozy-
gotes also displayed a significant 7.1% increase in LDL-C
levels (P0.0001), with a concomitant nonsignificant 7.5%
increase in apoB levels. Finally, heterozygotes presented with
a marked 2.2-fold increase in C-reactive protein (CRP)
plasma levels (P0.0001).
TABLE 1. Demographic and Lifestyle Characteristics and LCAT Activity Levels of




(n47) P (Unadjusted) P (Adjusted)*
Age, y 41.916.1 42.217.4 0.848   
Male gender, n (%) 27 (47) 29 (62) 0.062   
Diastolic blood
pressure, mm Hg
81.821.9 88.825.9 0.183 0.303
Systolic blood
pressure, mm Hg
131.624.0 126.534.5 0.951 0.909
Smoking, n (%) 8 (14) 10 (21) 0.007 0.015
Alcohol users, n (%) 41 (71) 33 (72) 0.805 0.580
LCAT activity,
nmol  mL1  h1†
25 14–18      
*P values for the variables blood pressure (diastolic and systolic), smoking, and alcohol use were
adjusted for age and sex.
†LCAT levels as measured against an apoA-I–containing liposome substrate. Data were derived
from previous publications.16,18,19,21
TABLE 2. Biochemical Characteristics of Heterozygotes for LCAT Gene Mutations
and Family Controls
Controls (n58) Heterozygotes (n47) P *
HDL-C, mg/dL 49.815.1 31.79.3 0.0001
ApoA-I, g/L 1.560.28 1.210.16 0.0001
Triglycerides, mg/dL 88.5 (58.4–121.2) 108.8 (77.0–175.2) 0.026
Total cholesterol, mg/dL 177.238.2 176.444.4 0.453
LDL-C, mg/dL 107.733.6 115.432.8 0.0001
ApoB, g/L 0.930.25 1.000.33 0.187
Lipoprotein(a), mg/L 104 (62–176) 93 (52–248) 0.819
hs-CRP, mg/L 2.00 (1.20–4.20) 4.40 (1.90–7.20) 0.0001
Values are means (SD) or median (interquartile range).
*Adjusted for age, gender, and smoking.
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IMT and Cardiovascular Events
Mean IMT values were 0.5910.08 mm for controls and
0.6230.13 mm for heterozygotes (Table 3). After adjust-
ment for age, gender, use of alcohol, and family, this
difference in average IMT proved to be highly statistically
significant (P0.0015). This probability value was obtained
with multivariate backward stepwise regression analysis,
whereby age, gender, and use of alcohol remained in the
model but smoking and blood pressure did not. Although the
family controls did not experience cardiovascular events, 1
male heterozygote had angina pectoris at age 50 years and a
myocardial infarction at age 54 years, and a second hetero-
zygote had a myocardial infarction at age 58 years.
Discussion
It has long been difficult to assess the risk of atherosclerosis
in individuals with genetically determined low HDL-C levels.
This knowledge, however, can provide important insight
when it comes to targeting HDL metabolism to reduce CVD
risk. After almost 40 years of LCAT research, the present
study provides evidence that heterozygotes for LCAT gene
defects, who present with an average 36% decrease in HDL-C
levels, exhibit an increased risk for atherosclerosis as as-
sessed by IMT measurements. These data suggest that intact
LCAT function is important in the protection against athero-
sclerotic vascular disease.
LCAT, Lipids, and Lipoproteins
The present analysis confirms the strong impact of LCAT
gene mutations on HDL-C levels. All LCAT gene defects
under study have previously been shown to underlie marked
loss of LCAT activity (30% to 42% compared with family
controls), and as a direct consequence, to result in 30% to
38% reductions in HDL-C levels16,19,21 (for a review, see
Pritchard and Hill13). LCAT is primarily active at the phos-
pholipid monolayer of nascent HDL particles, where it
converts cholesterol into cholesteryl ester on activation by its
cofactor, apoA-I. Even a single change in the amino acid
sequence of LCAT has been shown to result in a decreased
interaction with apoA-I, with a consequential decrease in
LCAT activity26 This will, in turn, cause defective maturation
of small HDL into larger, spherical, cholesteryl ester–en-
riched HDL and hence lower HDL-C levels. The data show
that this effect is not counteracted by upregulation of the
unaffected LCAT allele in heterozygotes or by other key
players in HDL metabolism. Additionally, the present study
shows the effect of LCAT mutations on plasma triglycerides
levels, as has been reported previously.20,27 Although het-
erozygotes presented with a moderate 22% increase in tri-
glyceride levels, homozygotes presented with a marked 337%
increase in triglyceride levels (data not shown). Mild hyper-
triglyceridemia is also observed in other genetic HDL defi-
ciencies.28,29 For LCAT, hepatic triglyceride overproduction
and reduced lipoprotein lipase activity, as found in LCAT-
deficient mice, may explain this phenotype.30 Finally, we
identified a small but significant increase in LDL-C levels
compared with controls, for which we have no explanation.
LCAT and Atherosclerosis
Despite the fact that LCAT has long been recognized as a key
regulator of HDL metabolism, the role of this enzyme in
human atherogenesis has remained controversial. Prospective
studies that have assessed LCAT activity or LCAT concen-
tration at baseline are nonexistent, whereas cross-sectional
observational studies have reported increased and decreased
LCAT activity in subjects with CVD.31,32 Initially, the para-
doxical finding of complete HDL deficiency and the reported
absence of CVD in LCAT-deficient patients has been used to
reject the hypothesis that HDL is important in the protection
against atherosclerosis. Potential mechanisms to explain these
findings were subsequently postulated, such as preferential
clearance of HDL fractions that have less atherogenic poten-
tial.33 In addition, decreased LDL-C and apoB levels have
also been put forward as an explanation for the lack of
marked CVD. In the large group of LCAT mutation carriers in
the present study, however, LDL-C was clearly not de-
creased, which refutes this argument.
Studies focusing on the role of LCAT in human athero-
sclerosis have thus far been hampered by the paucity of
clinical events in small numbers of individuals with LCAT
mutations. The advent of validated surrogate markers for
atherosclerosis has proved very useful in this context. IMT
measurements have been used to show that carriers of
ABCA1 and apoA-I defects are at increased risk for coronary
artery disease,8,34,35 which illustrates the power of this tool to
study small, interesting groups of patients. The present study
now shows that heterozygotes for LCAT mutations also have
increased atherosclerosis compared with family controls. This
finding was not based on a few heterozygous outliers with a
very thick carotid intima-media complex but on solid IMT
data. This is illustrated by the fact that the 30 heterozygotes
of the largest family (family 3) presented with a thicker IMT
than their 45 family control members (0.614 versus
0.589 mm). This effect, however, did not reach statistical
significance, which illustrates the need to recruit and study
more families with the same rare genetic disorder to answer
our primary research question. During the preparation of this
report, Ayyobi et al36 also reported vascular abnormalities in
a small cohort of 9 heterozygotes for 1 specific LCAT
mutation. The investigators could not, however, study family
controls, and because of the small number of study subjects,
these investigators could not draw conclusions regarding the
risk for atherosclerosis.36
A potential but dangerous drawback of studying athero-
sclerosis in relatively small cohorts, such as investigated here,
is the referral basis of the index patients. In this respect, we
would like to emphasize that the probands of the currently
TABLE 3. Carotid IMT and CVD Events for Heterozygotes for







Mean carotid IMT, mm 0.5910.08 0.6230.13 0.0015
Cardiovascular events, n (%) 0 (0) 2 (4)   
*Adjusted for all demographic and lifestyle characteristics that stayed in the
model with backward stepwise regression analysis (age, gender, and alcohol
use).
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studied families came to our attention because they experi-
enced corneal opacifications, or they were referred because of
previously identified low HDL-C levels. This excludes a bias
for selecting those families with LCAT mutations with an
increased or established risk for CVD. Exactly how reduced
LCAT function affects IMT, however, cannot be deduced
from the present study. LCAT mutations may directly com-
promise reverse cholesterol transport by reducing the flux of
cholesterol from cholesterol-loaded peripheral macrophages
to the HDL fraction. The markedly reduced HDL-C levels in
carriers also may affect endothelial function directly.37 Alter-
natively, loss of LCAT activity may cause enhanced oxida-
tion of LDL.38
LCAT and Inflammation
Elevated levels of CRP are an established predictor for
coronary artery disease,39 but there is much debate about
whether this plasma factor plays an active role in atheroscle-
rosis or whether it merely represents an innocent bystander.
We were surprised to find that hs-CRP levels were 2.2-fold
increased in the heterozygotes. From the present study,
however, it can not be appreciated whether increased levels of
CRP are a direct consequence of reduced LCAT activity or of
the consequentially reduced HDL-C levels. Pirro and col-
leagues40 also reported significantly higher CRP levels in
other subjects with hypoalphalipoproteinemia, which sug-
gests a proinflammatory status in subjects with low HDL-C
levels per se.
Concluding Remarks
Upregulation of LCAT function has been proposed as an
HDL-C increasing therapy, but its atheroprotective effects
have been questioned.41 The present study suggests that
increasing LCAT activity may reduce atherosclerosis pro-
gression, at least in subjects with subnormal levels of LCAT.
Efforts to develop LCAT protein therapy have failed, but
LCAT gene therapy protocols are more promising, as recently
illustrated by decreased atherosclerosis in dyslipidemic obese
mice42 after adenovirus-mediated transfer of the LCAT gene.
Also, Zhang et al43 recently showed that a similar strategy
increased reverse cholesterol transport in hamsters but, inter-
estingly, not in mice. The present report indicates that
increasing LCAT activity in plasma might be speculated to
result not only in increased HDL-C levels but also in
decreased concentrations of triglycerides and hs-CRP. More-
over, increased LCAT activity might also result in an aug-
mented capacity of HDL to exhibit antioxidative, antiinflam-
matory,44 and antithrombotic effects.
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